Research & Development Approach
Researchers have used the standard tools of biology and chemistry to develop many successful treatments, and we’ll continue to use them. However we recognize that these tools leave many drug targets—key proteins and nucleic acids known to play a role...
Privacy at Novartis
The responsible use of personal data is a core value at Novartis. Novartis Group fully respects privacy laws and is subject to an internal framework of privacy rules and policies. The internal transfer of data is governed by Binding Corporate Rules, so...About Kymriah®
Test
Patient resource
Discover useful resources for your patients undergoing KYMRIAH®therapy.
KYMRIAH ® consent form1) you have been fully informed about the risks and procedures involved in receiving [tisagenlecleucel] by your doctor 2) you...
Tasigna® CML - Clinical Papers
Rydapt® AML - Clinical Papers
Disclaimer:Glivec®
Glivec® is indicated for the · Treatment of adult patients and children 3 years of age and above with Ph+ chronic myeloid leukaemia (Ph+ -CML) in chronic phase, accelerated phase or blast crisis. Posology for CML in adult patients The recommended dosage...Disclaimer :Tasigna®
Indication: · Tasigna 150mg and 200mg are indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukaemia (CML) in the chronic phase. · Tasigna 200mg only is indicated also for the treatment...Disclaimer Afinitor
Afinitor 2.5, 5 & 10mg are indicated for the: 1. Treatment of patients with SEGA associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of...
×
Medical Information Request
×